Mohamed S. Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed S. Mohamed has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ahmed M. Samy
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
2 shared publications- Gamal Zayed
Al-Azhar University, Egypt
2 shared publications Wael A. Abdelhafez
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt
2 shared publications
Latest Publications
- 26 December 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (2) , 35
Optimization, in-vitro Release and in-vivo Evaluation of Gliquidone Nanoparticles
The present work embarks upon increasing the dissolution rate and the bioavailability of model anti-diabetic drug, gliquidone, a sulfonylurea class drug used for treating diabetes mellitus type 2....
- 26 December 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (2) , 35
Optimization, in-vitro Release and in-vivo Evaluation of Gliquidone Nanoparticles
The present work embarks upon increasing the dissolution rate and the bioavailability of model anti-diabetic drug, gliquidone, a sulfonylurea class drug used for treating diabetes mellitus type 2....
- 13 November 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (12) , 1973-1981
In vitro and in vivo characterization of fast dissolving tablets containing gliquidone–pluronic solid dispersion
The main objective of this study is to increase the dissolution rate of gliquidone using its solid dispersions with pluronic F-68 by solvent evaporation method. The solid dispersion of the drug with pluronic at ratio 1: 3 showed the highest dissolution efficiency (50.7%) after 10 minutes, so it was incorporated in fast dissolving tablets. Fourier transform infrared spectroscopy (FTIR) and Differential scanning calorimetry (DSC) were used to study the interaction between gliquidone and pluronic in the solid state. The FTIR spectroscopic studies revealed no chemical interaction between the drug and pluronic, while the DSC results indicated the amorphous state of gliquidone in the solid dispersion. A 32 full factorial design was used to study the effect of varying concentrations of croscarmellose and sodium starch glycolate as superdisintegrants on the disintegration time and the percentage released after 10 minutes. The optimized formula showed a disintegration time of 39.1±1.2 seconds and 85.43±5.16% released after 10 minutes and was selected for the in-vivo studies in rabbits. The selected formula showed significant enhancement of gliquidone bioavailability, about 1.8 times compared with the commercial Glurenor® tablets.
- 13 November 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (12) , 1973-1981
In vitro and in vivo characterization of fast dissolving tablets containing gliquidone–pluronic solid dispersion
The main objective of this study is to increase the dissolution rate of gliquidone using its solid dispersions with pluronic F-68 by solvent evaporation method. The solid dispersion of the drug with pluronic at ratio 1: 3 showed the highest dissolution efficiency (50.7%) after 10 minutes, so it was incorporated in fast dissolving tablets. Fourier transform infrared spectroscopy (FTIR) and Differential scanning calorimetry (DSC) were used to study the interaction between gliquidone and pluronic in the solid state. The FTIR spectroscopic studies revealed no chemical interaction between the drug and pluronic, while the DSC results indicated the amorphous state of gliquidone in the solid dispersion. A 32 full factorial design was used to study the effect of varying concentrations of croscarmellose and sodium starch glycolate as superdisintegrants on the disintegration time and the percentage released after 10 minutes. The optimized formula showed a disintegration time of 39.1±1.2 seconds and 85.43±5.16% released after 10 minutes and was selected for the in-vivo studies in rabbits. The selected formula showed significant enhancement of gliquidone bioavailability, about 1.8 times compared with the commercial Glurenor® tablets.